{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:04:19Z","timestamp":1775066659620,"version":"3.50.1"},"reference-count":102,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2003,10,1]],"date-time":"2003-10-01T00:00:00Z","timestamp":1064966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Microbiol Rev"],"published-print":{"date-parts":[[2003,10]]},"abstract":"<jats:sec>\n            <jats:title>SUMMARY<\/jats:title>\n            <jats:p>\n              The main risk factors for cytomegalovirus (CMV) disease in recipients of allogeneic stem cell transplants (SCT) are recipient CMV seropositivity and acute graft-versus-host disease. Currently, two antiviral strategies, prophylactic or preemptive antiviral treatment, are used for prevention of CMV disease. Preemptive treatment is most favorable when short-term (14-day) treatment is applied. Several methods are available for monitoring of CMV reactivation. PCR-based CMV DNA detection assays are the most sensitive methods; however, the clinical benefit of this high sensitivity is unclear. Even more, there is lack of clarity whether PCR tests can better be performed with plasma, whole blood, or peripheral blood leukocyte samples. Recovery of a CMV-specific CD8\n              <jats:sup>+<\/jats:sup>\n              cytotoxic-T-lymphocyte (CTL) response is necessary for preventing CMV reactivation and disease. Reconstitution of absolute CMV-specific CTL counts to values above 10 \u00d7 10\n              <jats:sup>6<\/jats:sup>\n              to 20 \u00d7 10\n              <jats:sup>6<\/jats:sup>\n              CTLs\/liter is associated with protection from CMV disease. In the near future, preemptive therapy might be withheld in patients with CMV reactivation who are shown to have adequate CMV-specific cytotoxic T-cell levels. Antiviral therapy with (val)acyclovir has been studied only as prophylactic treatment for prevention of CMV infection. High-dose oral valacyclovir is more effective than acyclovir when used in addition to preemptive treatment of CMV reactivation with ganciclovir or foscarnet. Three antiviral drugs have been tested for preemptive therapy of CMV reactivation and\/or treatment of CMV disease. Although intravenous ganciclovir is considered the drug of choice, foscarnet has similar efficacy and less toxicity, especially hematologic toxicity. Cidofovir has not been tested extensively, but so far the results are disappointing. Oral valganciclovir for preemptive treatment of SCT recipients is currently being studied. In addition to antiviral therapy, adoptive immunotherapy with CMV-specific cytotoxic T cells as prophylactic or preemptive therapy is a very elegant strategy; however, generation of these cells is expensive and time-consuming, and therefore the therapy is not available at every transplantation center. Magnetic selection of CMV-specific CD8\n              <jats:sup>+<\/jats:sup>\n              T cells from peripheral blood by using HLA class I-peptide tetramers may be very promising, making this strategy more accessible.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/cmr.16.4.647-657.2003","type":"journal-article","created":{"date-parts":[[2003,10,13]],"date-time":"2003-10-13T18:27:41Z","timestamp":1066069661000},"page":"647-657","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":69,"title":["Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants"],"prefix":"10.1128","volume":"16","author":[{"given":"Ellen","family":"Meijer","sequence":"first","affiliation":[{"name":"Department of Hematology, University Medical Center"},{"name":"Department of Virology, Eijkman-Winkler Institute Utrecht, The Netherlands"}]},{"given":"Greet J.","family":"Boland","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center"},{"name":"Department of Virology, Eijkman-Winkler Institute Utrecht, The Netherlands"}]},{"given":"Leo F.","family":"Verdonck","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center"},{"name":"Department of Virology, Eijkman-Winkler Institute Utrecht, The Netherlands"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/314449"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/323354"},{"key":"e_1_3_1_4_2","first-page":"783","volume":"13","year":"1994","unstructured":"Bacigalupo, A., E. Tedone, M. T. Van Lint, G. Trespi, M. Lonngren, M. A. Sanna, F. Moro, F. Frassoni, D. Occhini, F. Gualandi, T. Lamparelli, G. Hale, and A. M. Marmont. 1994. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections. Bone Marrow Transplant.13:783-788.","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_5_2","first-page":"753","volume":"13","year":"1994","unstructured":"Bacigalupo, A., M. T. Van Lint, E. Tedone, F. Moro, M. A. Sanna, M. Lonngren, G. Trespi, F. Frassoni, D. Occhini, F. Gualandi, T. Lamparelli, and A. M. Marmont. 1994. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marrow Transplant.13:753-758.","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.10.4063.bloodjournal88104063"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199707150-00020"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.11.3.533"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.5.1781"},{"key":"e_1_3_1_10_2","first-page":"4356","volume":"38","year":"2002","unstructured":"Boivin, G., R. Belanger, R. Delage, C. Beliveau, C. Demers, N. Goyette, and J. Roy. 2002. Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the Cobas Amplicor CMV monitor test after blood and marrow allogeneic transplantation. J. Clin. Microbiol.38:4356-4360.","journal-title":"J. Clin. Microbiol."},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(01)00209-8"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.1.246.246"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702450"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1943"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703251"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02519.x"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1232"},{"key":"e_1_3_1_18_2","first-page":"221","volume":"9","year":"1992","unstructured":"de Gast, G. C., G. J. Boland, A. M. Vlieger, R. A. de Weger, L. F. Verdonck, F. E. Zwann, and N. M. Jiwa. 1992. Abortive human cytomegalovirus infection in patients after allogeneic bone marrow transplantation. Bone Marrow Transplant.9:221-225.","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.3286"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.7.2815.2815"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702226"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.11.3916"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-10-777"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.140123497"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/517467"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.12.2.286"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1047"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05368.x"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.4.902-911.1999"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.5.1845-1853.2000"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3669-3671.2001"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-3-199302010-00003"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1358"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.12.4362-4369.2001"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/346240"},{"key":"e_1_3_1_36_2","first-page":"861","volume":"17","year":"1996","unstructured":"Hebart, H., C. Muller, J. Loffler, G. Jahn, and H. Einsele. 1996. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation. Bone Marrow Transplant.17:861-868.","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.5.1333-1337.1998"},{"key":"e_1_3_1_38_2","unstructured":"Reference deleted."},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3830"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703604"},{"key":"e_1_3_1_41_2","first-page":"2692","volume":"10","year":"1997","unstructured":"Hiyoshi, M., S. Tagawa, T. Takubo, K. Tanaka, T. Nakao, Y. Higeno, K. Tamura, M. Shimaoka, A. Fujii, M. Higashihata, Y. Yasui, T. Kim, A. Hiraoka, and N. Tatsumi. 1997. Evaluation of the Amplicor CMV test for direct detection of cytomegalovirus in plasma specimens. J. Clin. Microbiol.10:2692-2694.","journal-title":"J. Clin. Microbiol."},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/514569"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703178"},{"key":"e_1_3_1_44_2","unstructured":"Reference deleted."},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00518.x"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702805"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03106.x"},{"key":"e_1_3_1_48_2","unstructured":"Reference deleted."},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700801"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02849.x"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.7.1971.1971"},{"key":"e_1_3_1_52_2","unstructured":"Lim J. B. M. Provenzano M. Bettinotti and D. F. Stroncek. 2001. Identification of a new candidate HLA-A3 restricted CMV epitope as a target antigen to induce specific CMV cytotoxic lymphocytes. Blood98 : S780a. (Abstract 3244.)"},{"key":"e_1_3_1_53_2","first-page":"583","volume":"17","year":"1996","unstructured":"Ljungman, P., K. Lore, J. Aschan, S. Klaesson, I. Lewensohn-Fuchs, B. Lonnqvist, O. Ringden, J. Winiarski, and A. Ehrnst. 1996. Use of a semiquantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant recipients. Bone Marrow Transplant.17:583-587.","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_54_2","first-page":"565","volume":"18","year":"1996","unstructured":"Ljungman, P., G. Oberg, J. Aschan, A. Ehrnst, B. Lonnqvist, K. Pauksen, and P. Sulila. 1996. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients. Bone Marrow Transplant.18:565-568.","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161020-00004"},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.2.388"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.3050"},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002510000271"},{"key":"e_1_3_1_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702526"},{"key":"e_1_3_1_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703282"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.7.2536-2542.2000"},{"key":"e_1_3_1_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701439"},{"key":"e_1_3_1_63_2","first-page":"105","volume":"69","year":"1999","unstructured":"Matsunaga, T., S. Sakamaki, S. Ishigaki, K. Kohda, M. Takeda, J. Katoh, H. Kuroda, Y. Hirayama, T. Kusakabe, T. Akiyama, T. Kuga, Y. Niitsu, T. Masaoka, T. Sagawa, and Y. Matsumoto. 1999. Use of PCR serum in diagnosing and monitoring cytomegalovirus reactivation in bone marrow transplant recipients. Int. J. Hematol.69:105-111.","journal-title":"Int. J. Hematol."},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1086\/342332"},{"key":"e_1_3_1_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/153.3.478"},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198801143180202"},{"key":"e_1_3_1_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701302"},{"key":"e_1_3_1_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702227"},{"key":"e_1_3_1_69_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703542"},{"key":"e_1_3_1_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(99)00065-7"},{"key":"e_1_3_1_71_2","doi-asserted-by":"publisher","DOI":"10.1086\/338624"},{"key":"e_1_3_1_72_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770000189"},{"key":"e_1_3_1_73_2","unstructured":"Ozdemir E. L. S. St. John G. Gillespie S. Rowland-Jones R. E. Champlin J. J. Molldrem and K. V. Komanduri. 2001. Cytomegalovirus-specific CD8+ T cell recovery as measured by HLA-peptide tetramer staining is insufficient to control viremia following allogeneic stem cell transplantation. Blood98 : S389a. (Abstract 1638.)"},{"key":"e_1_3_1_74_2","first-page":"782","volume":"111","year":"2000","unstructured":"Peggs, K. S., W. Preiser, P. D. Kottaridis, N. McKeag, N. S. Brink, R. S. Tedder, A. H. Goldstone, D. C. Linch, and S. Mackinnon. 2000. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation. Br. J. Haematol.111:782-790.","journal-title":"Br. J. Haematol."},{"key":"e_1_3_1_75_2","unstructured":"Peggs K. S. Verfuerth A. Pizzey N. Khan P. Moss and S. Mackinnon. 2001. Cytomegalovirus-specific adoptive cellular therapy results in massive and persistent expansions of CMV-specific T-cells and significantly reduces the incidence of CMV reactivation following allogeneic transplantation. Blood98 : S779a. (Abstract 3240.)"},{"key":"e_1_3_1_76_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200104150-00010"},{"key":"e_1_3_1_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(00)00156-6"},{"key":"e_1_3_1_78_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700498"},{"key":"e_1_3_1_79_2","doi-asserted-by":"publisher","DOI":"10.1086\/314877"},{"key":"e_1_3_1_80_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198207013070102"},{"key":"e_1_3_1_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(99)00029-3"},{"key":"e_1_3_1_82_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-10-783"},{"key":"e_1_3_1_83_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.5.1373.1373"},{"key":"e_1_3_1_84_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/166.3.473"},{"key":"e_1_3_1_85_2","first-page":"813","volume":"17","year":"1996","unstructured":"Reusser, P., C. Cordonnier, H. Einsele, D. Engelhard, H. Link, A. Locasciulli, and P. Ljungman. 1996. European survey of herpesvirus resistance to antiviral drugs in bone marrow transplant recipients. Bone Marrow Transplant.17:813-817.","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_86_2","doi-asserted-by":"crossref","unstructured":"Reusser P. 2001. Oral valganciclovir: a new option for treatment of cytomegalovirus infection and disease in immunocompromised hosts. Expert Opin. Investig. Drugs10 : 1745-1753. (Erratum 11 : 733 2002.)","DOI":"10.1517\/13543784.10.9.1745"},{"key":"e_1_3_1_87_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.4.1159"},{"key":"e_1_3_1_88_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1352912"},{"key":"e_1_3_1_89_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104113241501"},{"key":"e_1_3_1_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703227"},{"key":"e_1_3_1_91_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701354"},{"key":"e_1_3_1_92_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.6.1360"},{"key":"e_1_3_1_93_2","unstructured":"Small T. N. E. P. Papadopoulos F. Boulad T. Kiehn J. Stiles K. Sepkowitz and R. J. O'Reilly. 2001. Outcome of pre-emptive or prophylactic anti-viral therapy to prevent CMV disease following T cell depleted related or unrelated BMT. Blood98 : S394a. (Abstract 1659.)"},{"key":"e_1_3_1_94_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.11.3938-3941.2001"},{"key":"e_1_3_1_95_2","unstructured":"Reference deleted."},{"key":"e_1_3_1_96_2","first-page":"144","volume":"87","year":"1994","unstructured":"van Prooyen, H. C., J. J. Visser, W. R. van Oostendorp, G. C. de Gast, and L. F. Verdonck. 1994. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br. J. Haematol.87:144-147.","journal-title":"Br. J. Haematol."},{"key":"e_1_3_1_97_2","first-page":"73","volume":"2","year":"1987","unstructured":"Verdonck, L. F., Y. C. E. de Graan-Hentzen, A. W. Dekker, G. C. Mudde, and G. C. de Gast. 1987. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant.2:73-78.","journal-title":"Bone Marrow Transplant."},{"key":"e_1_3_1_98_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.5.901"},{"key":"e_1_3_1_99_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703129"},{"key":"e_1_3_1_100_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510193331603"},{"key":"e_1_3_1_101_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-3-199302010-00004"},{"key":"e_1_3_1_102_2","doi-asserted-by":"publisher","DOI":"10.1086\/517468"},{"key":"e_1_3_1_103_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703513"}],"container-title":["Clinical Microbiology Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.16.4.647-657.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CMR.16.4.647-657.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T10:25:56Z","timestamp":1645611956000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CMR.16.4.647-657.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["10.1128\/CMR.16.4.647-657.2003"],"URL":"https:\/\/doi.org\/10.1128\/cmr.16.4.647-657.2003","relation":{},"ISSN":["0893-8512","1098-6618"],"issn-type":[{"value":"0893-8512","type":"print"},{"value":"1098-6618","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10]]},"assertion":[{"value":"2003-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}